Moguisteine

Last updated
Moguisteine
Moguisteine skeletal.png
Identifiers
  • Ethyl 3-{2-[(2-methoxyphenoxy)methyl]-1,3-thiazolidin-3-yl}-3-oxopropanoate
CAS Number
PubChem CID
ChemSpider
UNII
ChEMBL
CompTox Dashboard (EPA)
Chemical and physical data
Formula C16H21NO5S
Molar mass 339.41 g·mol−1
3D model (JSmol)
  • CCOC(=O)CC(=O)N1CCSC1COC2=CC=CC=C2OC
  • InChI=1S/C16H21NO5S/c1-3-21-16(19)10-14(18)17-8-9-23-15(17)11-22-13-7-5-4-6-12(13)20-2/h4-7,15H,3,8-11H2,1-2H3
  • Key:WSYVIAQNTFPTBI-UHFFFAOYSA-N

Moguisteine is a non-narcotic, peripherally acting antitussive. [1] In a small double-blind, randomized controlled trial, 200 mg of moguisteine suspension taken 3 times daily significantly reduced the frequency of coughing in patients with COPD, compared to placebo. [2] It has also been studied in small trials in comparison to codeine [3] and dextromethorphan, [4] and has similar efficacy to both. It has not been approved for use in the United States. [5]

It was discovered by searching for expectorants of the thiazolidine class, when compounds with a cough suppressant effect were accidentally found and moguisteine was selected as the most effective and safest representative of the class. [6] Its mechanism of action may be the activation of ATP-sensitive potassium channels. [7]

Related Research Articles

<span class="mw-page-title-main">Recreational use of dextromethorphan</span> Cough suppressant drug susceptible to misuse.

Dextromethorphan, or DXM, a common active ingredient found in many over-the-counter cough suppressant cold medicines, is used as a recreational drug and entheogen for its dissociative effects. Street names include Brownies, Dextro, Drix, Gel, Groove, Lean, Mega-perls, Poor man's ecstasy, Poor man's PCP, Red devils, Robo, Rojo, Rome, Skittles, Sizzurp, Sky and Velvet.

<span class="mw-page-title-main">Cold medicine</span> Medication taken to relieve cold symptoms

Cold medicines are a group of medications taken individually or in combination as a treatment for the symptoms of the common cold and similar conditions of the upper respiratory tract. The term encompasses a broad array of drugs, including analgesics, antihistamines and decongestants, among many others. It also includes drugs which are marketed as cough suppressants or antitussives, but their effectiveness in reducing cough symptoms is unclear or minimal.

<span class="mw-page-title-main">Dihydrocodeine</span> Opioid

Dihydrocodeine is a semi-synthetic opioid analgesic prescribed for pain or severe dyspnea, or as an antitussive, either alone or compounded with paracetamol (acetaminophen) or aspirin. It was developed in Germany in 1908 and first marketed in 1911.

<span class="mw-page-title-main">Dextrorphan</span> Psychoactive cough suppressant medication

Dextrorphan (DXO) is a psychoactive drug of the morphinan class which acts as an antitussive or cough suppressant and in high doses a dissociative hallucinogen. It is the dextrorotatory enantiomer of racemorphan; the levorotatory enantiomer is levorphanol. Dextrorphan is produced by O-demethylation of dextromethorphan by CYP2D6. Dextrorphan is an NMDA antagonist and contributes to the psychoactive effects of dextromethorphan.

<span class="mw-page-title-main">Noscapine</span> Chemical compound

Noscapine is a benzylisoquinoline alkaloid, of the phthalideisoquinoline structural subgroup, which has been isolated from numerous species of the family Papaveraceae. It lacks significant hypnotic, euphoric, or analgesic effects affording it with very low addictive potential. This agent is primarily used for its antitussive (cough-suppressing) effects.

<span class="mw-page-title-main">Phenyltoloxamine</span> Chemical compound

Phenyltoloxamine is an antihistamine with sedative and analgesic effects. It is available in combination with other drugs such as paracetamol (acetominophen).

<span class="mw-page-title-main">Dextromethorphan</span> Cough suppressant, antidepressant, and dissociative drug

Dextromethorphan (DXM), sold under the trade name Robitussin among others, is a cough suppressant used in many cough and cold medicines. It affects serotonin, norepinephrine, NMDA, and sigma-1 receptors in the brain, all of which have been implicated in the pathophysiology of depression. In 2022, the FDA approved the combination dextromethorphan/bupropion to serve as a rapid acting antidepressant in patients with major depressive disorder.

<span class="mw-page-title-main">Lefetamine</span> Chemical compound

Lefetamine (Santenol) is a drug which is a stimulant and also an analgesic with effects comparable to codeine.

<span class="mw-page-title-main">Pentoxyverine</span> Antitussive / cough suppressant

Pentoxyverine (rINN) or carbetapentane is an antitussive commonly used for cough associated with illnesses like common cold. It is sold over-the-counter as Solotuss, or in combination with other medications, especially decongestants. One such product is Certuss, a combination of guaifenesin and pentoxyverine. The drug has been available in the form of drops, suspensions and suppositories.

<span class="mw-page-title-main">Codeine</span> Opiate and prodrug of morphine used to treat pain

Codeine is an opiate and prodrug of morphine mainly used to treat pain, coughing, and diarrhea. It is also commonly used as a recreational drug. It is found naturally in the sap of the opium poppy, Papaver somniferum. It is typically used to treat mild to moderate degrees of pain. Greater benefit may occur when combined with paracetamol (acetaminophen) or a nonsteroidal anti-inflammatory drug (NSAID) such as aspirin or ibuprofen. Evidence does not support its use for acute cough suppression in children. In Europe, it is not recommended as a cough medicine in those under 12 years of age. It is generally taken by mouth. It typically starts working after half an hour, with maximum effect at two hours. Its effects last for about four to six hours. Codeine exhibits abuse potential similar to other opioid medications, including a risk of habituation and overdose.

<span class="mw-page-title-main">Clofedanol</span> Chemical compound

Clofedanol (INN) or chlophedianol (BAN), sold under the brand name Ninjacof among others, is a centrally acting cough suppressant used in the treatment of dry cough. Clofedanol has local anesthetic, antispasmodic, and antihistamine properties, and may have anticholinergic effects at high doses.

<span class="mw-page-title-main">Dimethoxanate</span> Chemical compound

Dimethoxanate is a cough suppressant of the phenothiazine class.

<span class="mw-page-title-main">Tipepidine</span> Chemical compound

Tipepidine (INN), also known as tipepidine hibenzate (JAN), is a synthetic, non-opioid antitussive and expectorant of the thiambutene class. It acts as an inhibitor of G protein-coupled inwardly-rectifying potassium channels (GIRKs). The drug was discovered in the 1950s, and was developed in Japan in 1959. It is used as the hibenzate and citrate salts.

<span class="mw-page-title-main">Cloperastine</span> Chemical compound

Cloperastine (INN) or cloperastin, in the forms of cloperastine hydrochloride (JAN) and cloperastine fendizoate, is an antitussive and antihistamine that is marketed as a cough suppressant in Japan, Hong Kong, and in some European countries. It was first introduced in 1972 in Japan, and then in Italy in 1981.

<span class="mw-page-title-main">Dibunate</span> Chemical compound

Dibunate is a cough suppressant. As the sodium salt, it has been marketed under the name Becantyl, Becantex, or Linctussal with a dosage of 20 to 30 mg, as either syrup or tablets.

<span class="mw-page-title-main">Zipeprol</span> Cough suppressant drug

Zipeprol is a centrally acting cough suppressant developed in France in the 1970s. It is not a morphinan derivative. Zipeprol acts as a local anaesthetic and has mucolytic, antihistamine and anticholinergic properties. It is sold with several brand names such as Zinolta and Respilene. It is not available in the United States or Canada and has been discontinued in Europe. It is still available in some countries in Asia and South America.

<span class="mw-page-title-main">Butamirate</span> Cough suppressant

Butamirate is a cough suppressant. It has been marketed in Europe and Mexico, but not in the United States.

<span class="mw-page-title-main">Oxeladin</span> Chemical compound

Oxeladin is a cough suppressant. It is a highly potent and effective drug used to treat all types of cough of various etiologies. It is not related to opium or its derivatives, so treatment with oxeladin is free of risk of dependence or addiction. Oxeladin has none of the side effects which are present when common antitussives, such as codeine and its derivatives, are used. It may be used at every age, as well as in patients with heart disease, since it has a high level of safety and a great selectivity to act on the bulbar centre of cough.

<span class="mw-page-title-main">Dimemorfan</span> Cough suppressant

Dimemorfan (INN), or dimemorfan phosphate (JAN), also known as 3,17-dimethylmorphinan, is an antitussive of the morphinan family that is widely used in Japan and is also marketed in Spain and Italy. It was developed by Yamanouchi Pharmaceutical and introduced in Japan in 1975. It was later introduced in Spain in 1981 and Japan in 1985.

<span class="mw-page-title-main">Opiate</span> Substance derived from opium

An opiate is an alkaloid substance derived from opium. It differs from the similar term opioid in that the latter is used to designate all substances, both natural and synthetic, that bind to opioid receptors in the brain. Opiates are alkaloid compounds naturally found in the opium poppy plant Papaver somniferum. The psychoactive compounds found in the opium plant include morphine, codeine, and thebaine. Opiates have long been used for a variety of medical conditions, with evidence of opiate trade and use for pain relief as early as the eighth century AD. Most opiates are considered drugs with moderate to high abuse potential and are listed on various "Substance-Control Schedules" under the Uniform Controlled Substances Act of the United States of America.

References

  1. Gallico L, Borghi A, Dalla Rosa C, Ceserani R, Tognella S (July 1994). "Moguisteine: a novel peripheral non-narcotic antitussive drug". British Journal of Pharmacology. 112 (3): 795–800. doi:10.1111/j.1476-5381.1994.tb13149.x. PMC   1910192 . PMID   7921605.
  2. Aversa C, Cazzola M, Clini V, Dal Negro R, Maiorano V, Tana F, Allegra L (1993). "Clinical trial of the efficacy and safety of moguisteine in patients with cough associated with chronic respiratory diseases". Drugs Under Experimental and Clinical Research. 19 (6): 273–9. PMID   8013271.
  3. Barnabè R, Berni F, Clini V, Pirrelli M, Pisani Ceretti A, Robuschi M, et al. (April 1995). "The efficacy and safety of moguisteine in comparison with codeine phosphate in patients with chronic cough". Monaldi Archives for Chest Disease = Archivio Monaldi per le Malattie del Torace. 50 (2): 93–7. PMID   7613554.
  4. Del Donno M, Aversa C, Corsico R, Foresi A, Grassi V, Malerba M, et al. (1994). "Efficacy and Safety of Moguisteine in Comparison with Dextromethorphan in Patients with Persistent Cough". Drug Investigation. 7 (2): 93–100. doi:10.1007/BF03257404. S2CID   72285850.
  5. Bolser DC (January 2006). "Cough suppressant and pharmacologic protussive therapy: ACCP evidence-based clinical practice guidelines". Chest. 129 (1 Suppl): 238S–249S. doi:10.1378/chest.129.1_suppl.238S. PMC   3127247 . PMID   16428717.
  6. Gandolfi CA, Di Domenico R, Spinelli S, Gallico L, Fiocchi L, Lotto A, et al. (February 1995). "N-acyl-2-substituted-1,3-thiazolidines, a new class of non-narcotic antitussive agents: studies leading to the discovery of ethyl 2-[(2-methoxyphenoxy)methyl]-beta-oxothiazolidine-3-propanoate". Journal of Medicinal Chemistry. 38 (3): 508–25. doi:10.1021/jm00003a014. PMID   7853344.
  7. Morita K, Kamei J (April 2000). "Involvement of ATP-sensitive K(+) channels in the anti-tussive effect of moguisteine". European Journal of Pharmacology. 395 (2): 161–4. doi:10.1016/s0014-2999(00)00197-7. PMID   10794823.